IP Library Granted Patent US 10,604,752
Granted Patent B2
US 10,604,752 · App. 16/031,819 · Granted Mar 31, 2020

Using nucleosome interacting protein domains to enhance targeted genome modification

Inventors: Fuqiang Chen (St. Louis, MO); Xiao Ding (St. Louis, MO); Yongmei Feng (St. Louis, MO); Gregory D. Davis (St. Louis, MO)
Assignee: Sigma-Aldrich Co. LLC
C12N15/102C12N9/22C12N15/113C12N15/85C12N15/907C12Q1/6897A61K48/005C07K2319/09C07K2319/10C07K2319/80C07K2319/81C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,604,752
App. No.
16/031,819
Granted
Mar 31, 2020
Kind
B2
Abstract

Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.

Claims (22)

1. A fusion protein comprising a clustered regularly interspersed short palindromic repeats (CRISPR) protein linked to at least one nucleosome interacting protein domain, wherein the CRISPR protein is a type II CRISPR/Cas9 nuclease from Streptococcus pyogenes Cas9 (SpCas9), Streptococcus thermophilus Cas9 (StCas9), Streptococcus pasteurianus (SpaCas9), Campylobacter jejuni Cas9 (CjCas9), Francisella novicida Cas9 (FnCas9), or Neisseria cinerea Cas9 (NcCas9), and the at least one nucleosome interacting protein domain is a high mobility group (HMG) box (HMGB) DNA binding domain, a HMG nucleosome-binding (HMGN) protein, a central globular domain from a histone H1 variant comprising SEQ ID NO:45, or a combination thereof, and wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein at its N-terminus, C-terminus, or a combination thereof.

2. The fusion protein of claim 1 , wherein the at least one nucleosome interacting protein domain is HMGB1 box A domain, HMGN1 protein, HMGN2 protein, HMGN3a protein, HMGN3b protein, a central globular domain from a histone H1 variant comprising SEQ ID NO: 45, or a combination thereof.

3. The fusion protein of claim 1 , wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein directly via a chemical bond, indirectly via a linker, or a combination thereof.

4. The fusion protein of claim 1 , further comprising at least one nuclear localization signal, at least one cell-penetrating domain, at least one marker domain, or a combination thereof.

5. The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence as set forth in SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:72, or SEQ ID NO:73.

6. The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence as set forth in SEQ ID NO:78 or SEQ ID NO:79.

7. The fusion protein of claim 1 , wherein the type II CRISPR/Cas9 nuclease is from Streptococcus pyogenes Cas9 (SpCas9).

8. The fusion protein of claim 1 , wherein the type II CRISPR/Cas9 nuclease is from Streptococcus thermophilus Cas9 (StCas9).

9. The fusion protein of claim 1 , wherein the type II CRISPR/Cas9 nuclease is from Streptococcus pasteurianus (SpaCas9).

10. The fusion protein of claim 1 , wherein the type II CRISPR/Cas9 nuclease is from Campylobacter jejuni Cas9 (CjCas9).

11. The fusion protein of claim 1 , wherein the type II CRISPR/Cas9 nuclease is from Francisella novicida Cas9 (FnCas9).

12. The fusion protein of claim 1 , wherein the type II CRISPR/Cas9 nuclease is from Neisseria cinerea Cas9 (NcCas9).

13. A protein-RNA complex comprising at least one fusion protein of claim 1 and at least one guide RNA.

14. A nucleic acid encoding a fusion protein comprising a clustered regularly interspersed short palindromic repeats (CRISPR) protein linked to at least one nucleosome interacting protein domain, wherein the CRISPR protein is a type II CRISPR/Cas9 nuclease from Streptococcus pyogenes Cas9 (SpCas9), Streptococcus thermophilus Cas9 (StCas9), Streptococcus pasteurianus (SpaCas9), Campylobacter jejuni Cas9 (CjCas9), Francisella novicida Cas9 (FnCas9), or Neisseria cinerea Cas9 (NcCas9), and the at least one nucleosome interacting protein domain is a high mobility group (HMG) box (HMGB) DNA binding domain, a HMG nucleosome-binding (HMGN) protein, a central globular domain from a histone H1 variant comprising SEQ ID NO: 45, or a combination thereof, and wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein at its N-terminus, C-terminus, or a combination thereof.

15. The nucleic acid of claim 14 , which is codon optimized for translation in a eukaryotic cell.

16. The nucleic acid of claim 15 , which is part of a viral vector, a plasmid vector, or a self-replicating RNA.

17. A fusion protein comprising a clustered regularly interspersed short palindromic repeats (CRISPR) protein linked to at least one nucleosome interacting protein domain, wherein the CRISPR protein is a type II CRISPR/Cas9 protein from Streptococcus pyogenes Cas9 (SpCas9), Streptococcus thermophilus Cas9 (StCas9), Streptococcus pasteurianus (SpaCas9), Campylobacter jejuni Cas9 (CjCas9), Francisella novicida Cas9 (FnCas9), or Neisseria cinerea Cas9 (NcCas9), modified to lack all nuclease activity and linked to a non-nuclease domain and the at least one nucleosome interacting protein domain is a high mobility group (HMG) box (HMGB) DNA binding domain, a HMG nucleosome-binding (HMGN) protein, a central globular domain from a histone H1 variant comprising SEQ ID NO: 45, or a combination thereof, and wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein at its N-terminus, C-terminus, or a combination thereof.

18. The fusion protein of claim 17 , wherein the non-nuclease domain has cytosine deaminase activity, histone acetyltransferase activity, transcriptional activation activity, or transcriptional repressor activity.

19. A protein-RNA complex comprising at least one fusion protein of claim 17 , and at least one guide RNA.

20. A nucleic acid encoding a fusion protein comprising a clustered regularly interspersed short palindromic repeats (CRISPR) protein linked to at least one nucleosome interacting protein domain, wherein the CRISPR protein is a type II CRISPR/Cas9 protein from Streptococcus pyogenes Cas9 (SpCas9), Streptococcus thermophilus Cas9 (StCas9), Streptococcus pasteurianus (SpaCas9), Campylobacter jejuni Cas9 (CjCas9), Francisella novicida Cas9 (FnCas9), or Neisseria cinerea Cas9 (NcCas9), modified to lack all nuclease activity and linked to a non-nuclease domain and the at least one nucleosome interacting protein domain is a high mobility group (HMG) box (HMGB) DNA binding domain, a HMG nucleosome-binding (HMGN) protein, a central globular domain from a histone H1 variant comprising SEQ ID NO: 45, or a combination thereof, and wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein at its N-terminus, C-terminus, or a combination thereof.

21. The nucleic acid of claim 20 , which is codon optimized for translation in a eukaryotic cell.

22. The nucleic acid of claim 21 , which is part of a viral vector, a plasmid vector, or a self-replicating RNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2018
From: CHEN, FUQIANG; DING, XIAO; FENG, YONGMEI; DAVIS, GREGORY D.
To: SIGMA-ALDRICH CO. LLC
Reel/Frame 046430/0479 →
Continuity (2)
Provisional Application 62531222 · Jul 11, 2017
Related Publication 20190017042A1 · Jan 17, 2019
Cited By (3)
US 12,201,699 US 12,221,606 US 12,338,436